Cryo-Cell International, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Cover
- Cover Page
Financial Statements
Notes to Financial Statements
Accounting Policies
- Description of Business, Basis of Presentation and Significant Accounting Policies (Policies)
Notes Tables
Notes Details

License Agreements

License Agreements	9 Months Ended
Aug. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
License Agreements	Note 8 – License Agreements The Company has definitive license agreements to market the Company’s umbilical cord blood stem cell programs in Costa Rica, El Salvador, Guatemala, Honduras, Nicaragua and Panama (“affiliates”). Under the marketing agreements, the Company earns processing and storage revenues from affiliates that store specimens in the Company's facility.

License Agreements

9 Months Ended

Aug. 31, 2024

Goodwill and Intangible Assets Disclosure [Abstract]

License Agreements

Note 8 – License Agreements

The Company has definitive license agreements to market the Company’s umbilical cord blood stem cell programs in Costa Rica, El Salvador, Guatemala, Honduras, Nicaragua and Panama (“affiliates”). Under the marketing agreements, the Company earns processing and storage revenues from affiliates that store specimens in the Company's facility.